Format

Send to

Choose Destination
Eur J Cancer. 2014 Nov;50(16):2846-54. doi: 10.1016/j.ejca.2014.07.018. Epub 2014 Aug 21.

Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples.

Author information

1
Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain. Electronic address: lalemany@iconcologia.net.
2
Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
3
Hospital Oncológico, Quito, Ecuador.
4
Mexican Oncology Hospital, IMSS, Mexico, DF, Mexico.
5
Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Hospital General de L'Hospitalet, Barcelona, Spain.
6
Department of Gynaecology and Obstetrics, Medical University of Vienna, Comprehensive Cancer Center, Vienna, Austria.
7
Instituto de Ginecologia da Universidad Federal Do Rio de Janeiro-UFRJ, Rio de Janeiro, Brazil.
8
Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; CIBER en Epidemiología y Salud Pública (CIBERESP), Spain.
9
Laboratoire Cerba, Department de Pathologie, Paris, France.
10
Klinikum Wolfsburg, Wolfsburg, Germany.
11
DDL Diagnostic Laboratory, Rijswijk, The Netherlands.
12
Instituto Nacional de Cancerología, Bogotá, Colombia.
13
CHU Reims, Hopital Maison Blanche, Laboratoire Pol Bouin, Reims, France; INSERM UMR-S903, Reims, France.
14
WestMead Hospital, Sydney, Australia.
15
Jagiellonian University Medical College, Krakow, Poland.
16
Queen Elizabeth Hospital, Sheriff Hill, UK.
17
Faculty of Medicine, Eduardo Mondlane University and Maputo Central Hospital, Maputo, Mozambique.
18
Centro de Oncología Preventiva, Universidad de Chile, Santiago, Chile.
19
National Cancer Center, Seoul, South Korea.
20
Third Faculty of Medicine and Faculty Hospital King's Wineyards, Prague, Czech Republic.
21
Medical University of Lublin, Lublin, Poland.
22
Hospital Universitari de Bellvitge, Barcelona, Spain.
23
Centro de Investigación Epidemiológica en Salud Sexual y Reproductiva - CIESAR, Hospital General San Juan de Dios - HGSJDD, Guatemala, Guatemala.
24
Manchester Royal Infirmary, Manchester, United Kingdom.
25
Laboratorio de Anatomia Patológica del Hospital de la Mujer, Montevideo, Uruguay.
26
Instituto Potosino de Investigación Científica y Tecnológica, AC (IPICYT), San Luis Potosí, Mexico.
27
German Cancer Research Center (DKFZ), Heidelberg, Germany.
28
Cancer Institute of Colombia, Colombia.

Abstract

AIM:

This work describes the human papillomavirus (HPV) prevalence and the HPV type distribution in a large series of vaginal intraepithelial neoplasia (VAIN) grades 2/3 and vaginal cancer worldwide.

METHODS:

We analysed 189 VAIN 2/3 and 408 invasive vaginal cancer cases collected from 31 countries from 1986 to 2011. After histopathological evaluation of sectioned formalin-fixed paraffin-embedded samples, HPV DNA detection and typing was performed using the SPF-10/DNA enzyme immunoassay (DEIA)/LiPA25 system (version 1). A subset of 146 vaginal cancers was tested for p16(INK4a) expression, a cellular surrogate marker for HPV transformation. Prevalence ratios were estimated using multivariate Poisson regression with robust variance.

RESULTS:

HPV DNA was detected in 74% (95% confidence interval (CI): 70-78%) of invasive cancers and in 96% (95% CI: 92-98%) of VAIN 2/3. Among cancers, the highest detection rates were observed in warty-basaloid subtype of squamous cell carcinomas, and in younger ages. Concerning the type-specific distribution, HPV16 was the most frequently type detected in both precancerous and cancerous lesions (59%). p16(INK4a) overexpression was found in 87% of HPV DNA positive vaginal cancer cases.

CONCLUSIONS:

HPV was identified in a large proportion of invasive vaginal cancers and in almost all VAIN 2/3. HPV16 was the most common type detected. A large impact in the reduction of the burden of vaginal neoplastic lesions is expected among vaccinated cohorts.

KEYWORDS:

Human papillomavirus; Vaccine; Vaginal cancer; Vaginal intraepithelial neoplasia

PMID:
25155250
DOI:
10.1016/j.ejca.2014.07.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center